Results 211 to 220 of about 109,722 (264)
Blinatumomab for Pediatric High-Risk B-Cell Precursor Acute Lymphoblastic Leukemia: Safety, MRD Response and Survival in a Single-Center Retrospective Cohort. [PDF]
Immunotargets TherMitura-Lesiuk M +6 more
europepmc +1 more source
Redefining the role of the transfusion medicine physician in the era of advanced cellular therapies
Transfusion, EarlyView.
Eric A. Gehrie, Kevin J. Land
wiley +1 more source
Concurrent Development of B-Cell Lymphoblastic Lymphoma and Histiocytic Sarcoma in a C57BL/6 Laboratory Mouse: A Case Report. [PDF]
Vet Med SciLee Y +6 more
europepmc +1 more source
Correction to Favorable and poor prognosis B-cell precursor acute lymphoblastic leukemia subtypes reveal distinct leukemic cell properties when interacting with mesenchymal stem cells, differentially modifying their cell stemness and leukemia chemoresistance. [PDF]
J Cell Commun Signaleuropepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Nature, 1975
LYMPHOCYTES are motile cells whose movement in vivo seems to be directed, yet investigators over many years have repeatedly failed to show chemotaxis of lymphocytes in vitro. There have been some recent reports that lymphocytes migrate into micropore filters towards substances placed below the filter1–3, but this migration was not found to be ...
Russell, R J +3 more
openaire +2 more sources
LYMPHOCYTES are motile cells whose movement in vivo seems to be directed, yet investigators over many years have repeatedly failed to show chemotaxis of lymphocytes in vitro. There have been some recent reports that lymphocytes migrate into micropore filters towards substances placed below the filter1–3, but this migration was not found to be ...
Russell, R J +3 more
openaire +2 more sources
Hematology/Oncology Clinics of North America, 2001
Recent advances in the unique clinicopathologic entity of lymphoblastic lymphoma (and its variants) are discussed in this article, which details the natural history, molecular biology, prognosis, and outcome with various chemotherapy regimens. Improved outcome with the newer intensive chemotherapy regimens and the role of modalities such as autologous ...
D A, Thomas, H M, Kantarjian
openaire +2 more sources
Recent advances in the unique clinicopathologic entity of lymphoblastic lymphoma (and its variants) are discussed in this article, which details the natural history, molecular biology, prognosis, and outcome with various chemotherapy regimens. Improved outcome with the newer intensive chemotherapy regimens and the role of modalities such as autologous ...
D A, Thomas, H M, Kantarjian
openaire +2 more sources
Critical Reviews in Oncology/Hematology, 2011
Lymphoblastic lymphoma (LBL) is a neoplasm of immature B cells committed to the B-(B-LBL) or T-cell lineage (T-LBL) that accounts for approximately 2% of all lymphomas. From a histopathological point of view, blasts may be encountered in tissue biopsy and/or bone marrow (BM).
Cortelazzo S +3 more
openaire +3 more sources
Lymphoblastic lymphoma (LBL) is a neoplasm of immature B cells committed to the B-(B-LBL) or T-cell lineage (T-LBL) that accounts for approximately 2% of all lymphomas. From a histopathological point of view, blasts may be encountered in tissue biopsy and/or bone marrow (BM).
Cortelazzo S +3 more
openaire +3 more sources
Lymphoblastic Lymphoma with the Phenotype of Common Acute Lymphoblastic Leukemia
American Journal of Clinical Pathology, 1983Immunologic phenotyping of lymphoblastic lymphomas has shown that most of these are tumors of T-cell origin. In this report, we describe two patients with biopsy-proven lymphoblastic lymphoma whose tumors had no T-cell markers when tested by immunoperoxidase with a large panel of monoclonal antibodies.
B P Croker +2 more
exaly +3 more sources
Pediatric Clinics of North America, 1997
Advances in the molecular and immunologic characterization of leukemic cells have greatly aided the diagnosis and risk assignment of ALL, as well as the monitoring of bone marrow samples for minimal residual disease. Currently, 75% of childhood cases have biologically and therapeutically relevant genetic abnormalities.
openaire +2 more sources
Advances in the molecular and immunologic characterization of leukemic cells have greatly aided the diagnosis and risk assignment of ALL, as well as the monitoring of bone marrow samples for minimal residual disease. Currently, 75% of childhood cases have biologically and therapeutically relevant genetic abnormalities.
openaire +2 more sources
Hematology, 2002
AbstractThis is a comprehensive overview on the most recent developments in diagnosis and treatment of acute lymphoblastic leukemia (ALL).Dr. Dieter Hoelzer and colleagues give an overview of current chemotherapy approaches, prognostic factors, risk stratification, and new treatment options such as tyrosine kinase inhibitors and monoclonal antibodies ...
Dieter, Hoelzer +7 more
openaire +4 more sources
AbstractThis is a comprehensive overview on the most recent developments in diagnosis and treatment of acute lymphoblastic leukemia (ALL).Dr. Dieter Hoelzer and colleagues give an overview of current chemotherapy approaches, prognostic factors, risk stratification, and new treatment options such as tyrosine kinase inhibitors and monoclonal antibodies ...
Dieter, Hoelzer +7 more
openaire +4 more sources